BioSpace News Archive

The race is on in the CD47 field, and Brisbane-based player Arch Oncology just upped the bet with a $105 million Series C raise.

In phase one of the two-part program, access to tofersen will be granted on an individual basis to SOD1-ALS patients with an ALS Functional Rating Scale - Revised (ALSFRS-R) slope decline greater than or equal to 2 points per month.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, invites the holders of securities issued by the Company to attend the Annual and Extraordinary General Meetings of Shareholders on Thursday 27 May 2021.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of efficacy and safety results from a previously reported Phase 2b clinical trial with nebulized ensifentrine added on to maintenance bronchodilator therapy in symptomatic chronic obstructive pulmonary disease patients.

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announced its CEO and CSO Dr. Kunwar Shailubhai and the chair of its Scientific Advisory Committee, Dr Howard Weiner, will participate in a fireside chat via a video link on Wednesday, 28 April 2021 at 10:30 a.m. EDT to provide updates on the Company.

-Establishment of New Business Alliance and Facility to Provide Comprehensive Support for New Product Launches for Manufacturers Aiming to Enter Japan Market-

So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year.

Yellow fever is a serious, potentially deadly flu-like disease spread by Aedes aegypti mosquitoes, which also transmit dengue and Zika viruses.

Whole exome sequencing is expected to receive a staggering demand as DNA sequencing and its advances pave the way in the research field with the transformation of genomics.

Value-based health care is a type of service, and the providers, such as hospitals, are paid on the basis of patient experience, cost, efficiency, quality, health outcome of the patient.